Premium
Intent and subsequent initiation of human papillomavirus vaccine among young cancer survivors
Author(s) -
Cherven Brooke,
Castellino Sharon M.,
Chen Yanjun,
Wong F. Lennie,
York Jocelyn M.,
WasilewskiMasker Karen,
Hudson Melissa M.,
Bhatia Smita,
Klosky James L.,
Landier Wendy
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32379
Subject(s) - medicine , odds ratio , vaccination , confidence interval , immunization , logistic regression , human papillomavirus vaccine , human papillomavirus , cancer registry , young adult , cancer , hpv vaccines , demography , immunology , cervical cancer , hpv infection , gardasil , immune system , sociology
Background Despite an increased risk of subsequent human papillomavirus (HPV)–related malignancies, HPV vaccine initiation rates among cancer survivors remain critically low. The purpose of this study was to determine the relationship between HPV vaccine intent and subsequent vaccine initiation among cancer survivors by linking data from a cross‐sectional survey with state‐based immunization registry records. Methods Cancer survivors who were 9 to 26 years old were surveyed 1 to 5 years after their treatment to assess their HPV vaccine initiation status, HPV vaccine intent, sociodemographic factors, and vaccine‐related health beliefs. HPV vaccine doses/dates were abstracted from the Georgia Registry for Immunization Transactions for 3.5 years after survey participation. Logistic regression models identified factors associated with vaccine intent and subsequent vaccine initiation. Results Among survivors who were HPV vaccine–naive at survey participation (n = 103), factors associated with vaccine intent included the following: 1) provider recommendation for the HPV vaccine (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.4‐18.1; P = .014), 2) positive general attitude toward vaccines (OR, 4.8; 95% CI, 2.0‐11.2; P < .001), and 3) perceived severity of HPV disease (OR, 3.5; 95% CI, 1.2‐9.9; P = .02). Of the vaccine‐naive patients, 28 initiated the HPV vaccine at a median of 1.1 years after the survey. Initiation was more likely among survivors who had reported vaccine intent (OR, 3.9; 95% CI, 1.2‐12.5; P = .02) and was less likely among older survivors (OR per year, 0.7; 95% CI, 0.6‐0.9; P < .001). Conclusions These findings suggest that provider recommendation for the HPV vaccine plays a role in establishing intent, which then translates into subsequent initiation.